Table 2.
Ref.
|
Item 1
|
Item 2
|
Item 3
|
Item 4
|
Item 5
|
Item 6
|
Item 7
|
Item 8
|
Item 9
|
Item 10
|
Item 11
|
Scores
|
Picca et al[19], 2020 | Yes | Yes | Yes | Yes | Yes | Yes | 6 | |||||
Van Tongeren et al[16], 2005 | Yes | Yes | Yes | Yes | Yes | Yes | 6 | |||||
Xu et al[17], 2021 | Yes | Yes | Yes | Yes | Yes | Yes | 6 | |||||
Lim et al[18], 2021 | Yes | Yes | Yes | Yes | Yes | Yes | 6 | |||||
Zhang et al[22], 2020 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | 8 | |||
Margiotta et al[20], 2020 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | 7 | ||||
Zhang et al[21], 2022 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | 7 |
Yes is one point, the total number of stars represents a number of points. Item 1: Define the source of information (survey, record review)? Item 2: Inclusion and exclusion criteria for exposed and unexposed subjects (cases and controls) or refer to previous publications? Item 3: Indicate time period used for identifying patients? Item 4: Indicate whether or not subjects were consecutive if not population-based? Item 5: Indicate if evaluators of subjective components of study were masked to other aspects of the status of the participant? Item 6: Describe any assessments undertaken for quality assurance purposes (e.g., testretest of primary out come measuroments)? Item 7: Explain any patient exclusions from analysis? Item 8: Describe how confounding was assessed and/or controlled? Item 9: If applicable, explain how missing data were handled in the analysis? Item 10: Summarize patient response rates and completeness of data collection? Item 11: Clarify what follow-up, if any, was expected and the percentage of patients for which incomplete data or follow-up was obtained?